This afternoon we watched Exelixis drop -9.2% to a price of $33.09 per share. The Mid-Cap Biotechnology company is now trading -7.08% below its average target price of $35.61. Analysts have set target prices ranging from $23.0 to $42.0 per share for Exelixis, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 4.9%, and a short ratio of 5.24. Since 1.78% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 89.1% of Exelixis's shares being owned by this investor type.
Institutions Invested in Exelixis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 11% | 32,076,418 | $1,061,248,260 |
| 2024-09-30 | Vanguard Group Inc | 10% | 29,307,502 | $969,638,676 |
| 2024-09-30 | Farallon Capital Management LLC | 9% | 25,410,500 | $840,706,369 |
| 2024-09-30 | Renaissance Technologies, LLC | 5% | 15,359,916 | $508,182,806 |
| 2024-09-30 | State Street Corporation | 4% | 11,443,668 | $378,613,745 |
| 2024-09-30 | LSV Asset Management | 3% | 8,102,377 | $268,067,135 |
| 2024-09-30 | Fuller & Thaler Asset Management Inc. | 2% | 6,922,628 | $229,035,141 |
| 2024-09-30 | Dimensional Fund Advisors LP | 2% | 5,252,974 | $173,794,639 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 5,162,924 | $170,815,335 |
| 2024-09-30 | JP Morgan Chase & Company | 2% | 4,430,653 | $146,588,150 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Exelixis.
